Latest Enbrel Stories
BURLINGTON, Mass., Sept.
NEW YORK, Aug.
WALTHAM, Mass., March 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed dermatologists view Abbott/Eisai's Humira as the most efficacious therapy for the treatment of moderate to severe psoriasis.
VIENNA, Va., Feb. 22 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM) and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis (RA) in a mouse model.
WALTHAM, Mass., Feb.
WALTHAM, Mass., Nov.
WALTHAM, Mass., Oct.
THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Oct. 16 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) and Pfizer (NYSE: PFE), today announced new scientific data about ENBREL being presented at the 2009 American College of Rheumatology (ACR) Scientific Meeting in Philadelphia, Pa., from Oct.
THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Aug.
Newly Approved Simponi is Expected to Achieve Strong Uptake in this Niche Market, According to a New Report from Decision Resources WALTHAM, Mass., April 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the availability of Amgen/Wyeth/Takeda's Enbrel, Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade, and Abbott/Eisai's Humira has driven dramatic growth in the spondyloarthropathy (SpA)...
- Withering but not falling off, as a blossom that persists on a twig after flowering.